FOLH1 and nonpapillary renal cell carcinoma: Rizzo et al. in their meta-analysis published in 2023, which included 14 predominantly retrospective studies (total number of patients 397 (range 8–66), including 331 patients with ccRCC), evaluated the diagnostic accuracy of PSMA PET/CT in RCC diagnostics, regardless of the type of PSMA ligand used, both at the stage of primary disease advancement and during restaging of ccRCC in patients with suspected metastatic disease [70].